BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

546 related articles for article (PubMed ID: 29916022)

  • 1. Mechanisms Associated with TDP-43 Neurotoxicity in ALS/FTLD.
    Shenouda M; Zhang AB; Weichert A; Robertson J
    Adv Neurobiol; 2018; 20():239-263. PubMed ID: 29916022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The RNA-binding motif 45 (RBM45) protein accumulates in inclusion bodies in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP) patients.
    Collins M; Riascos D; Kovalik T; An J; Krupa K; Krupa K; Hood BL; Conrads TP; Renton AE; Traynor BJ; Bowser R
    Acta Neuropathol; 2012 Nov; 124(5):717-32. PubMed ID: 22993125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of TDP-43 in the pathogenesis of ALS and FTLD.
    Baralle M; Buratti E; Baralle FE
    Biochem Soc Trans; 2013 Dec; 41(6):1536-40. PubMed ID: 24256250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How do the RNA-binding proteins TDP-43 and FUS relate to amyotrophic lateral sclerosis and frontotemporal degeneration, and to each other?
    Baloh RH
    Curr Opin Neurol; 2012 Dec; 25(6):701-7. PubMed ID: 23041957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct TDP-43 inclusion morphologies in frontotemporal lobar degeneration with and without amyotrophic lateral sclerosis.
    Tan RH; Yang Y; Kim WS; Dobson-Stone C; Kwok JB; Kiernan MC; Halliday GM
    Acta Neuropathol Commun; 2017 Oct; 5(1):76. PubMed ID: 29078806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transportin 1 accumulates specifically with FET proteins but no other transportin cargos in FTLD-FUS and is absent in FUS inclusions in ALS with FUS mutations.
    Neumann M; Valori CF; Ansorge O; Kretzschmar HA; Munoz DG; Kusaka H; Yokota O; Ishihara K; Ang LC; Bilbao JM; Mackenzie IR
    Acta Neuropathol; 2012 Nov; 124(5):705-16. PubMed ID: 22842875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aberrant interaction between FUS and SFPQ in neurons in a wide range of FTLD spectrum diseases.
    Ishigaki S; Riku Y; Fujioka Y; Endo K; Iwade N; Kawai K; Ishibashi M; Yokoi S; Katsuno M; Watanabe H; Mori K; Akagi A; Yokota O; Terada S; Kawakami I; Suzuki N; Warita H; Aoki M; Yoshida M; Sobue G
    Brain; 2020 Aug; 143(8):2398-2405. PubMed ID: 32770214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amyotrophic lateral sclerosis and frontotemporal lobar degeneration: a spectrum of TDP-43 proteinopathies.
    Geser F; Lee VM; Trojanowski JQ
    Neuropathology; 2010 Apr; 30(2):103-12. PubMed ID: 20102519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TDP-43 transgenic mice develop spastic paralysis and neuronal inclusions characteristic of ALS and frontotemporal lobar degeneration.
    Wils H; Kleinberger G; Janssens J; Pereson S; Joris G; Cuijt I; Smits V; Ceuterick-de Groote C; Van Broeckhoven C; Kumar-Singh S
    Proc Natl Acad Sci U S A; 2010 Feb; 107(8):3858-63. PubMed ID: 20133711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Possible concurrence of TDP-43, tau and other proteins in amyotrophic lateral sclerosis/frontotemporal lobar degeneration.
    Takeda T
    Neuropathology; 2018 Feb; 38(1):72-81. PubMed ID: 28960544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathological mechanisms underlying TDP-43 driven neurodegeneration in FTLD-ALS spectrum disorders.
    Janssens J; Van Broeckhoven C
    Hum Mol Genet; 2013 Oct; 22(R1):R77-87. PubMed ID: 23900071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular basis of amyotrophic lateral sclerosis.
    Liscic RM; Breljak D
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar; 35(2):370-2. PubMed ID: 20655970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RNA-binding proteins with prion-like domains in ALS and FTLD-U.
    Gitler AD; Shorter J
    Prion; 2011; 5(3):179-87. PubMed ID: 21847013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytoplasmic poly-GA aggregates impair nuclear import of TDP-43 in C9orf72 ALS/FTLD.
    Khosravi B; Hartmann H; May S; Möhl C; Ederle H; Michaelsen M; Schludi MH; Dormann D; Edbauer D
    Hum Mol Genet; 2017 Feb; 26(4):790-800. PubMed ID: 28040728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular Mechanisms Underlying TDP-43 Pathology in Cellular and Animal Models of ALS and FTLD.
    Wood A; Gurfinkel Y; Polain N; Lamont W; Lyn Rea S
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Requirements for stress granule recruitment of fused in sarcoma (FUS) and TAR DNA-binding protein of 43 kDa (TDP-43).
    Bentmann E; Neumann M; Tahirovic S; Rodde R; Dormann D; Haass C
    J Biol Chem; 2012 Jun; 287(27):23079-94. PubMed ID: 22563080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frontotemporal lobar degeneration and amyotrophic lateral sclerosis: molecular similarities and differences.
    Neumann M
    Rev Neurol (Paris); 2013 Oct; 169(10):793-8. PubMed ID: 24011641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TDP-43 and FUS: a nuclear affair.
    Dormann D; Haass C
    Trends Neurosci; 2011 Jul; 34(7):339-48. PubMed ID: 21700347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lower motor neuron involvement in TAR DNA-binding protein of 43 kDa-related frontotemporal lobar degeneration and amyotrophic lateral sclerosis.
    Riku Y; Watanabe H; Yoshida M; Tatsumi S; Mimuro M; Iwasaki Y; Katsuno M; Iguchi Y; Masuda M; Senda J; Ishigaki S; Udagawa T; Sobue G
    JAMA Neurol; 2014 Feb; 71(2):172-9. PubMed ID: 24378564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical and pathological spectrum of TDP-43 associated ALS].
    Onodera O; Yokoseki A; Tan CF; Ishihara T; Nishiira Y; Toyoshima Y; Kakita A; Nishizawa M; Takahashi H
    Rinsho Shinkeigaku; 2010 Nov; 50(11):940-2. PubMed ID: 21921519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.